Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Department of Immunology, Tokyo Medical University, Tokyo, Japan.
Commun Biol. 2021 May 14;4(1):581. doi: 10.1038/s42003-021-02111-3.
The coinhibitory receptor, PD-1, is of major importance for the suppression of T cell activation in various types of immune responses. A high-resolution imaging study showed that PD-1 forms a coinhibitory signalosome, "PD-1 microcluster", with the phosphatase, SHP2, to dephosphorylate the TCR/CD3 complex and its downstream signaling molecules. Such a consecutive reaction entirely depended on PD-1-PD-L1/2 binding. PD-L2 is expressed on professional antigen-presenting cells and also on some tumor cells, which possibly explains the discrepant efficacy of immune checkpoint therapy for PD-L1-negative tumors. Here, we performed precise imaging analysis of PD-L2 forming PD-1-PD-L2 clusters associating with SHP2. PD-L2 could compete with PD-L1 for binding to PD-1, occupying the same space at TCR microclusters. The PD-1 microcluster formation was inhibited by certain mAbs with functional consequences. Thus, PD-1 microcluster formation provides a visible index for the effectiveness of anti-PD-1- or anti-PD-L1/2-mediated T cell suppression. PD-L2 may exert immune suppressive responses cooperatively with PD-L1 on the microcluster scale.
抑制性受体 PD-1 对于各种类型免疫反应中 T 细胞的激活抑制具有重要意义。一项高分辨率成像研究表明,PD-1 与磷酸酶 SHP2 形成抑制性信号小体“PD-1 微簇”,使 TCR/CD3 复合物及其下游信号分子去磷酸化。这种连续反应完全依赖于 PD-1-PD-L1/2 的结合。PD-L2 表达于专业抗原呈递细胞上,也表达于某些肿瘤细胞上,这可能解释了免疫检查点疗法对 PD-L1 阴性肿瘤疗效不一致的原因。在这里,我们对形成 PD-1-PD-L2 簇并与 SHP2 相关的 PD-L2 进行了精确的成像分析。PD-L2 可以与 PD-L1 竞争与 PD-1 的结合,占据 TCR 微簇的相同空间。PD-1 微簇的形成被具有功能后果的某些 mAb 抑制。因此,PD-1 微簇的形成提供了一个可见的指标,用于评估抗 PD-1 或抗 PD-L1/2 介导的 T 细胞抑制的有效性。PD-L2 可能与 PD-L1 一起在微簇水平上发挥免疫抑制作用。